| Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting | 10/31 07:00 | businesswire.com |
| Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease | 10/03 07:00 | businesswire.com |
| Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable | 06/20 07:00 | businesswire.com |
| Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease | 06/13 07:00 | businesswire.com |
| Aldeyra Therapeutics to Host Investor Roundtable Q&A | 06/12 07:00 | businesswire.com |
| Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission | 06/10 13:25 | seekingalpha.com |
| Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference | 05/29 07:00 | businesswire.com |
| Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year? | 05/14 10:46 | zacks.com |
| Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease | 05/08 07:00 | businesswire.com |
| ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024 | 05/03 08:52 | investorplace.com |